126 related articles for article (PubMed ID: 37541419)
21. Immune Subtypes and Immune Landscape Analysis of Endometrial Carcinoma.
Liang L; Zhu Y; Li J; Zeng J; Yuan G; Wu L
J Immunol; 2022 Oct; 209(8):1606-1614. PubMed ID: 36096644
[TBL] [Abstract][Full Text] [Related]
22. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
23. A seven-m6A regulator-related CpG site-based prognostic signature for endometrial carcinoma.
Zhang X; Pang X; Huang Y; Qian S
Medicine (Baltimore); 2021 Jul; 100(29):e26648. PubMed ID: 34398021
[TBL] [Abstract][Full Text] [Related]
24. The role of an immune signature for prognosis and immunotherapy response in endometrial cancer.
Meng Y; Yang Y; Zhang Y; Yang X; Li X; Hu C
Am J Transl Res; 2021; 13(2):532-548. PubMed ID: 33594308
[TBL] [Abstract][Full Text] [Related]
25. Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer.
Liu J; Chen X; Jiang Y; Cheng W
Int Immunopharmacol; 2020 Sep; 86():106735. PubMed ID: 32619957
[TBL] [Abstract][Full Text] [Related]
26. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
[TBL] [Abstract][Full Text] [Related]
27. Identification of cuproptosis-related subtypes, establishment of a prognostic model and tumor immune landscape in endometrial carcinoma.
Shan J; Geng R; Zhang Y; Wei J; Liu J; Bai J
Comput Biol Med; 2022 Oct; 149():105988. PubMed ID: 36007289
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
Li BL; Wan XP
J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
[TBL] [Abstract][Full Text] [Related]
29. TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Yang Q; Yu B; Sun J
Biomed Res Int; 2020; 2020():4625123. PubMed ID: 33282948
[TBL] [Abstract][Full Text] [Related]
30. A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response.
Liu X; Shi X; Guo W; Ke Y; Li Y; Pan S; Li X; Liu M; Liu M; Wang Y; Ruan Q; Ma H
Int J Gen Med; 2021; 14():5845-5862. PubMed ID: 34566425
[TBL] [Abstract][Full Text] [Related]
31. A Novel Defined Pyroptosis-Related Gene Signature for Predicting the Prognosis of Endometrial Cancer.
Liu S; Zeng C; Lv H; Zhang Y; Xiong H; Tang H
Dis Markers; 2022; 2022():7570494. PubMed ID: 36601599
[TBL] [Abstract][Full Text] [Related]
32. Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma.
Wu Y; Wang J; Ge L; Hu Q
Oxid Med Cell Longev; 2022; 2022():5130648. PubMed ID: 35251475
[TBL] [Abstract][Full Text] [Related]
33. Novel insights into tumorigenesis and prognosis of endometrial cancer through systematic investigation and validation on mitophagy-related signature.
Sun R; Zhou X; Wang T; Liu Y; Wei L; Qiu Z; Qiu C; Jiang J
Hum Cell; 2023 Jul; 36(4):1548-1563. PubMed ID: 37266867
[TBL] [Abstract][Full Text] [Related]
34. [Characterization of Cell Subsets Associated With Prognosis of Osteosarcoma Based on Single-Cell Sequencing Data].
Wang ST; Zhu HR; Xu SJ; Gui P; Chen MZ; Li ZX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Oct; 45(5):773-782. PubMed ID: 37927019
[TBL] [Abstract][Full Text] [Related]
35. Identifying prognostic biomarkers in endometrial carcinoma based on ceRNA network.
Zhao D; Ren C; Yao Y; Wang Q; Li F; Li Y; Jiang A; Wang G
J Cell Biochem; 2020 Mar; 121(3):2437-2446. PubMed ID: 31692050
[TBL] [Abstract][Full Text] [Related]
36. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
37. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma.
Cheng P; Ma J; Zheng X; Zhou C; Chen X
Sci Rep; 2021 Jun; 11(1):12608. PubMed ID: 34131259
[TBL] [Abstract][Full Text] [Related]
39. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
Hu B; Meng Y; Qu C; Wang BY; Xiu DR
Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
[TBL] [Abstract][Full Text] [Related]
40. A novel predictive model based on inflammatory response-related genes for predicting endometrial cancer prognosis and its experimental validation.
Wang Y; Wang B; Ma X
Aging (Albany NY); 2023 Jun; 15(11):4844-4860. PubMed ID: 37276865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
